Pulse Biosciences Grants Equity Incentive Awards to New Employees
16 October 2018 - 7:24AM
Business Wire
Pulse Biosciences, Inc. (NASDAQ: PLSE), a novel medical therapy
company bringing to market its proprietary Nano-Pulse Stimulation™
platform, announced today that the Compensation Committee of the
company’s Board of Directors granted non-qualified stock options
covering an aggregate of 20,750 shares of Pulse Biosciences common
stock to four new non-executive employees under the Pulse
Biosciences 2017 Inducement Equity Incentive Plan on October 15,
2018.
The 2017 Inducement Equity Incentive Plan is used exclusively to
grant equity awards to individuals who were not previously an
employee or non-employee director of Pulse Biosciences as an
inducement material to such individual's entering into employment
with Pulse Biosciences in accordance with Nasdaq Marketplace Rule
5635(c)(4).
The options have an exercise price of $11.00 per share, which is
equal to the closing price of Pulse Biosciences common stock on
October 15, 2018. The 20,750 shares underlying the option grants
will vest and become exercisable as to 25% of the shares on the
first anniversary of the recipient’s start date, and will vest and
become exercisable as to the remaining 75% of the shares in 36
equal monthly installments following the first anniversary of the
recipient’s start date, subject to the recipient’s continued
employment with Pulse Biosciences on these vesting dates. The
options are subject to the terms and conditions of the 2017
Inducement Equity Incentive Plan and the award agreements entered
into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a novel medical therapy company
bringing to market its proprietary Nano-Pulse Stimulation™ (“NPS™”)
platform. NPS is a novel, precise, non-thermal, treatment
technology delivering nanosecond duration energy pulses that impact
cells in treated tissue while sparing surrounding acellular tissue.
NPS’s unique mechanism of action disrupts the functions of internal
cell structures while maintaining the outer cell membrane
initiating a cascade of events within the cell that results in
regulated cell death. In pre-clinical studies, NPS has demonstrated
an ability to induce immunogenic cell death in cancer cell lines.
The novel characteristics of NPS’s unique mechanism of action has
the potential to significantly benefit patients for multiple
medical applications, including dermatology, the Company’s first
planned commercial application, with future potential in other
disease states where an enhanced immune response may be
beneficial. More information is available at
www.pulsebiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181015005912/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@pulsebiosciences.comorSolebury TroutGitanjali Jain Ogawa,
646-378-2949gogawa@troutgroup.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024